Glodé 10/14
LEONARD MICHAEL GLODÉ, M.D.
Business Address
Urologic Oncology
Anschutz Outpatient Pavilion
1665 Aurora Court
Suite 1004 - Campus Box F710
Aurora, CO 80045
Office Telephone: (720) 848-2543
Email: Mike.Glode@ucdenver.edu
Place of Birth
Chadron, NE
Citizenship
USA
Marital Status
Married, 1969 to Mary Patricia Rose Glodé, M.D., 3 children
Education
1965
1965-1968
1972
Certification
1973
1975
1981
Chadron High School, Chadron, Nebraska, Valedictorian
University of Nebraska, Lincoln, NE; Zoology Major
Washington University School of Medicine, St Louis, MO
Degree: M.D.
National Board of Medical Examiners (Cert. No. 123284)
American Board of Internal Medicine (Cert. No. 51200)
American Board of Internal Medicine, Medical Oncology
Subspecialty
Professional Experience
1972
Parkland Memorial Hospital
Straight Medical Intern, Parkland Memorial Hospital, Dallas, Texas
1973
University of Texas Southwestern Medical School
Straight Medical Resident, University of Texas Southwestern Medical School,
Dallas, Texas
1974-1976
Laboratory of Microbiology and Immunology
Research Associate, NIH, NIDR, Laboratory of Microbiology and
Immunology, Bethesda, Maryland
1976-1978
Harvard Medical School
Fellow in Medical Oncology, Dana Farber Cancer Institute, Harvard Medical
School, Boston, MA
1978-1983
University of Colorado Health Sciences Center
Assistant Professor of Medicine, Division of Medical Oncology,
University of Colorado Health Sciences Center, Denver, Colorado
1983-1991
University of Colorado Health Sciences Center
1
Glodé 10/14
1986-1987
1991-Present
Associate Professor of Medicine, Division of Medical Oncology,
University of Colorado Health Sciences Center, Denver, Colorado
University of Helsinki
Fogarty Fellow in Molecular Biology, University of Helsinki
University of Colorado Health Sciences Center
Professor of Medicine, Division of Medical Oncology, University of Colorado
Health Sciences Center, Denver, Colorado
Military Service
1974-1976
U.S. Public Health Service
1976-1994
USPHS Reserve
Licenses
1975 Maryland
1976 Massachusetts
1978 Colorado
Societies
Theta Nu (premedical honorary fraternity)
Alpha Omega Alpha (medical honorary)
American Society of Clinical Oncology
American Association for Cancer Research
Western Society for Clinical Investigation
Western Association of Physicians
American College of Physicians
Honors
1965-1968
1968-1969
1969-1970
1970-1971
1970-1971
1971-1972
1980-1982
1982
1986-1987
1993-2005
1996-2006
1998
1999
20002003
2003
2008
2008
Deans List, University of Nebraska (4.0 cumulative average)
Richard G. Brookings Prize for Academic Excellence (Washington University
School of Medicine)
Roche Award (Washington University School of Medicine)
Richard G. Brookings Prize (Washington University School of Medicine)
Merck Award (Washington University School of Medicine)
Alpha Omega Alpha Book Award (Washington University School of Medicine)
American Cancer Society Junior Faculty Clinical Fellow
Invited Speaker, ACS Science Writer's Seminar
Fogarty Senior International Fellow, Molecular Biology, University of Helsinki
Best Doctors in America
Best Doctors in America, Medical Advisory Board
Excellence in Teaching Award, Medical Student Council, The University of
Colorado School of Medicine
University of Colorado Innovations in Teaching Award, HSC Campus
Robert Rifkin Chair for Prostate Cancer Research
Excellence in Teaching Award, The University of Colorado School of
Medicine Class of 2003
Board of Directors Appreciation Award, American Society Clinical Oncology
Statesman Award, American Society of Clinical Oncology
Fellow, American College of Physicians
2
Glodé 10/14
Committees/Administration/Education
1.
Medical Director, Gene Therapy Program 1990-96
2.
Organizer, American Association of Cancer Research Workshop, "Molecular Biology for
Clinical Oncologists, July 1992-2000
3.
Course Director, Med 6622 Medical School Curriculum, 1987-1995
4.
Medical Director, Prostate Research Clinic 1996-Present
5.
Ad Hoc Member, National Institutes of Health Study Section on Experimental
Therapeutics 2
6.
Ad Hoc Member, NCI study section for Gene Therapy RFA's
7.
Ad Hoc Member, American Cancer Society Study Section on Hematology
8.
Internship Selection Committee - 1988-1995
9.
Medical Review Committee, W.W. Smith Charitable Trust, Bryn Mawr, PA: 1992-1995
10.
Editorial Committee, Annual Review of Medicine: Selected Topics in the Clinical
Sciences, 1991.
11.
Chair, Molecular Medicine Education Committee, American Society of Clinical Oncology,
1994
12.
President, Faculty Senate, University of Colorado School of Medicine 1994-95
13.
Vice Chair, ASCO Education Committee, 1994-1995
14.
Chair, ASCO Education Committee, 1995-1996
15.
Board of Directors, Best Doctors in America, 1997-2002
16.
Editor-in-Chief, ASCO Online, 1996-2004
17.
Member, Advisory and Oversight Board for Informatics Infrastructure, National Cancer
Institute, 1998-2000
18.
University Physicians Inc. (UPI) Board of Directors 2001-2003
19.
President Elect, Faculty Council, University of Colorado Health Sciences Center, 2001-03
20.
Board of Directors, Gonex, Cedus Inc. 1996-Present
21.
Course Director, Oncology Section, Med 6000 Pathophysiology, 1998-2003
22.
Member, UPI Negotiating Principles Committee, 2001
23.
Editorial Board Member, Molecular Cancer Therapeutics, 2001-Present
24.
Councilor, Alpha Omega Alpha, Colorado chapter, 2000-2004
25.
Faculty, American Society of Clinical Oncology Annual Meetings 1994, 2008,2009
26.
President, Faculty Assembly, University of Colorado Health Sciences Center, 2003-2005
27.
Editorial Board Member, Cancer Biology & Therapy, 2002-2007
28.
Associate Director for Outreach, University of Colorado Cancer Center 200829.
Editorial Board, Oncoogy, 2011Reviewer
1996-2003
1998-2001
1998-Present
2001-Present
Founding Editor and Editor-in-Chief, ASCO OnLine (http://www.asco.org)
Associate Editor, Clinical Cancer Research
American Journal of Respiratory and Critical Care Medicine
Editorial Board member, Molecular Cancer Therapeutics
Ad Hoc Reviewer for Cancer Research, Science, American Review of
Respiratory Diseases, Cancer, New England Journal of Medicine,
Journal of the National Cancer Institute and Annals of Internal
Medicine
3
Glodé 10/14
Patents
1.
GnRH Analogs for Destroying Gonadotrophs: 5,378,688 issued Jan. 3, 1995; T M Nett,
and L M Glodé
2.
Method for Sterilizing Animals using Hormone-Toxin Conjugate Compounds: 5,488,036
issued Jan. 30, 1996; T M Nett, and L M Glodé
3.
Hormone-Toxin Conjugate Compounds: 5,492,893 issued Feb. 20, 1996; T M Nett, and L
M Glodé
4.
Method for Inactivating Gonadotrophs: 5,631,229 issued May 20, 1997; T M Nett, and L
M Glodé
5.
Method for Treating Cancer: 5,707,964 issued Jan. 13, 1998, T M Nett, and L M Glodé
6.
Hormone-Nuclease Compounds and Method for Regulating Hormone Related Diseases:
5,786,457 issued Jul. 28, 1998; T M Nett, L M Glodé and M Karpeisky
7.
GnRH-Nuclease Compounds and Method for Regulating Hormone Related Diseases:
6,103,881 issued Aug. 15, 2000; T M Nett, L M Glodé and M Karpeisky
8.
Hormone-recombinant toxin compounds and methods for using same, issued Dec 4 2001; T
M Nett, L M Glodé, M Wieczorek, and P Jarosz
9.
Method for controlling animal populations utilizing a sterilant projectile, 6,419,655, issued
Jul 16, 2002; T M Nett and L M Glodé
10.
Method for Isolation of Epithelial Cells from a Solution: 6,653,129 issued May 18, 2004;
N H Bander, L M Glodé, and C In Suh
LIST OF PUBLICATIONS
Publications in Peer Reviewed Journals
1.
Rosenstreich DL, and Glodé LM: Difference in B cell mitogen responsiveness between
closely related strains of mice. J Immunology 115:770-780, 1975.
2.
Glodé LM, Scher I, Osborne B, and Rosenstreich DL: Cellular mechanism of endotoxin
unresponsiveness in C3H/HeJ mice. J Immunology 116:454-467, 1976.
3.
Glodé LM, and Rosenstreich DL: Genetic control of B cell activation by bacterial
lipopolysaccharide is mediated by multiple distinct genes or alleles. J Immunology
117:2061-2066, 1976.
4.
Rosenstreich DL, Glodé LM, and Mergenhagen SE: The action of endotoxin on lymphoid
cells. J Infect Dis 136:S239-245, 1977.
5.
Glodé LM, Mergenhagen SE, and Rosenstreich DL: Significant contribution of spleen
cells in mediating the lethal effects of endotoxin in vivo. Infection & Immunity 14:626630, 1977.
6.
Rosenstreich DL, Glodé LM, Wahl LM, Sandberg AL, and Mergenhagen SE: Analysis of
the cellular defect of the endotoxin unresponsive C3H/HeJ mouse. (Am. Soc. Microbiol.
Conf. on Endotoxin, Bacterial Antigens, and Host Response). in: Microbiology, D.
Schlesinger (ed), Amer. Soc. Microbiol., Washington, D.C., 1977.
7.
Glodé LM, Jacques A, Mergenhagen SE, and Rosenstreich DL: Resistance of
macrophages from C3H/HeJ mice to the in vitro cytotoxic effects of endotoxin. J
Immunology 119:162-166, 1977.
8.
Glodé LM, Greene HL, and Bikel I: Cystathionase in normal and leukemic cells. Cancer
Treat Rep 63:1081-1088, 1979.
9.
Glodé LM, Pitman SW, Ensminger WD, Rosowsky A, Papathanasopoulos N, and Frei E
III: A Phase I study of high dose aminopterin with leucovorin rescue in patients with
advanced metastatic tumors. Cancer Res 39:3707-3714, 1979.
4
Glodé 10/14
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
Ensminger WD, Rosowsky A, Raso V, Levin DC, Glodé LM, Come S, Steele G, and Frei
E III: A clinical-pharmacologic evaluation of hepatic arterial infusions of 5-fluoro-2'deoxyuridine and 5-fluorouracil. Cancer Res 38:3784-3792, 1979.
Ryan JL, Glodé LM, and Rosenstreich DL: Lack of responsiveness of C3H/HeJ
macrophages to lipopolysaccharide: The cellular basis of LPS stimulated metabolism. J
Immunology 122:932-935, 1979.
Wahl LM, Rosenstreich DL, Glodé LM, Sandberg AL, and Mergenhagen SE: Defective
prostaglandin synthesis by C3H/HeJ mouse macrophages stimulated with endotoxin
preparations. Infection & Immunity 23(1):8-13, 1979.
Glodé LM: Dose limiting extramedullary toxicity of high dose chemotherapy. Exp.
Hematol. 7 (Suppl. 5):265-278, 1979.
Glodé LM, Kriegler MP, and Livingston DM: Cysteine auxotrophy of human
lymphoblasts is associated with decreased amounts of intracellular cystathionase protein.
Biochemistry 20(5):1306-1311, 1981.
Glodé LM, Epstein A, and Smith C: Reduced gamma cystathionase protein content in
human malignant leukemic cell lines as measured by immunoassay with monoclonal
antibody. Cancer Res 41:2249-2254, 1981.
Glodé LM, Robinson J, and Gould SF: Protection from cyclophosphamide induced
testicular damage by an analogue of gonadotropin releasing hormone. Lancet I:1132-1134,
1981.
Hartmann DW, Robinson WA, Mangalik A, Glodé LM, and Triebel F: Unanticipated side
effects from treatment with high dose mechlorethamine in patients with malignant
melanoma. Cancer Treat Rep 65:327-328, 1981.
Hartmann DW, Robinson WA, Morton NJ, Mangalik A, and Glodé LM: High dose
nitrogen mustard (NH2) with autologous nonfrozen bone marrow transplantation in
advanced malignant melanoma. A Phase I trial. Blut 42:209-220, 1981.
Glodé LM, Montgomery RL, Smith CG, and Link D: Use of monoclonal antibody to
increase sensitivity and specificity in quantitative immunodiffusion assays. J Immun
Methods 48:l3-22, l982.
Thomas MR, Robinson WA, Koeppler H, Dantas ME, Glodé LM, Morton NJ: Treatment
of advanced malignant melanoma with high dose chemotherapy and autologous bone
marrow transplantation. Preliminary results--Phase I study. Am J Clin Onc 5:611-622,
1982.
Glodé LM, Robinson WA, Hartmann DW, Klein J, Thomas MR and Morton NJ:
Autologous bone marrow transplantation in the therapy of small cell carcinoma of the
lung. Cancer Res 42:4270-4275, 1982.
Glodé LM, Robinson J, Gould SF, Nett TM, and Merrill D: Protection of spermatogenesis
during chemotherapy. Drugs in Exptl Clin Res VIII(4):367-378, 1982.
Link D, Drebing C, and Glodé LM: Cystathionase: A potential cytoplasmic marker of
hematopoietic differentiation. Blut 47:31-39, 1983.
Gould SF, Powell D, Nett T, and Glodé LM: A rat model for chemotherapy induced male
infertility. Arch Andrology 11:141-150, 1983.
Dantas ME, Brown JP, Thomas MR, Robinson WA, and Glodé LM: Detection of
melanoma cells in bone marrow using monoclonal antibodies: a comparison of
fluorescence activated cell sorting (FACS) and conventional immunofluorescence (IF).
Cancer 52(6);949-953, 1983.
Chitambar CR, Robinson WA, and Glodé LM: Familial leukemia and aplastic anemia
associated with monosomy 7. Am J Med 75:756-762, 1983.
5
Glodé 10/14
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
Geier JM, Braun TJ, Gross CE, Kindt GW, and Glodé LM: Extracerebral toxicity of
continuous intracarotid 2'deoxy-5-fluorouridine via implanted Infusaid 400 pump in brain
tumor patients. Surg Forum 34:530-533, 1983.
Garnick MB and Glodé LM: (Writing Committee for the Leuprolide Study Group):
Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Eng J Med
311:1281-1285, 1984.
Thomas MR, Robinson WA, Koeppler H, Dantas M, Drebing C, and Glodé LM:
Autologous marrow transplantation for patients with chronic myelogenous leukemia
(CML) in blast crisis. Am J Hemat 16:105-112, 1984.
Santen RJ, Demers LM, Max DT, Smith J, Stein BS, and Glodé LM: Long-term effects of
administration of a gonadotropin-releasing hormone super agonist analog in men with
prostatic carcinoma. J Clin Endo & Metab 58:397-400, 1984.
Manni A, Santen RJ, Boucher A, Lipton A, Harvey H, Drago J, Rohner T, Haagensen D,
Glodé LM, and Santner SJ: Evaluation of CEA and GCDFP-15 plasma level during
hormonally induced cancer stimulation. Anticancer Res 4:141- 144, 1984.
Thomas MR, Robinson WA, Mughal TI, and Glodé LM: Tumor lysis syndrome following
VP-16-213 in chronic myeloid leukemia in blast crisis. Amer J Hemat 16:185-188, 1984.
Glodé LM, Robinson J, and Horwitz LD: Scrotal hypothermia and testicular blood flow in
the dog - absence of thermal regulation. J Androl 5:227-229, 1984.
Manni A, Santen RJ, Boucher A, Lipton A, Harvey H, Simmonds M, White D, Gordon R,
Ronher T, Drago J, Wettlaufer J, and Glodé LM: Hormone stimulation and chemotherapy
in advanced prostate cancer: Preliminary results of a prospective controlled clinical trial.
Anticancer Res 5(2):161-165, 1985.
Smith Jr. JA, Glodé LM, Wettlaufer JM, Stein BS, Glass AG, Max DT, Anbar D, Jagst CL,
and Murphy GP: Clinical effects of a gonadotropin-releasing hormone analogue in
metastatic carcinoma of prostate. Urology 25:106-114, 1985.
Garnick MB, Glodé LM, Smith JA, and Max D (for the Leuprolide Study Group):
Leuprolide: A review of its effects in comparison with diethylstil boestrol in the treatment
of advanced cancer of the prostate. Brit J Clin Prac 39:73-76, 1985.
Montgomery RR, Kunicki TJ and Glodé LM: Use of monoclonal antibody to increase the
sensitivity and specificity of precipitating immunoassays and cell surface binding
immunoassays. Methods in Enzymology 121:702-717, 1986.
Glodé LM: The biology of gonadotropin-releasing hormone and its analogs. J Urology
27:16-19, 1986.
Mughal T, Glodé LM, Smith H, Geyer JM, Braun T, Klingensmith W, and Kindt G: Phase
I clinical trial of intracarotid bis-chloroethylnitrosoureas (BCNU) and 2' dioxy-5fluorouridine (FUDR) in malignant astrocytomas. J Neuro Onc 3:291-296, 1986.
Thomas MR, Robinson WA, Mughal T, Morton N, and Glodé LM: Recovery of blood
and bone marrow stem cells following intense chemotherapy and autologous bone marrow
transplantation. Oncology 43:273-277, 1986.
Maxwell IH, Maxwell F and Glodé LM: Regulated expression of a diphtheria toxin Achain gene transfected into human cells: A possible strategy for inducing cancer cell
suicide. Cancer Res 46:4660-4664, 1986.
Braunschweiger PG, Glodé LM, Maring EM, Machus K, and Reynolds BV: Biologic
implications of androgen dependent changes in proton-NMR relaxation times in rat ventral
prostate. The Prostate 9:283-294, 1986.
6
Glodé 10/14
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
Manni A, Santen RJ, Boucher AE, Lipton A, Harvey H, Simmonds M, White-Hershey D,
Gordon RA, Rohner TJ, Drago J, Wettlaufer J, and Glodé LM: Androgen priming and
response to chemotherapy in advanced prostate cancer. J Urol 136:1242-1246, 1986.
Manni A, Santen R, Boucher A, Lipton A, Harvey A, Simmonds M, White-Hershey D,
Gordon R, Rohner T, Drago J, Wettlaufer J, and Glodé LM: Hormone stimulation and
chemotherapy in advanced prostate cancer: Interim analysis of an ongoing randomized
trial. Anticancer Res 6(2):309-314, 1986.
Manni A, Santen RJ, Boucher A, Lipton A, Harvey H, White D, Simmonds M, Gordon R,
Rohner T, Drago J, Wettlaufer J, Glodé LM: Androgen priming and chemotherapy in
advanced prostate cancer. J Endo Invest 10(2):32, 1987.
Glodé LM and Smith JA: Long-term suppression of luteinizing hormone, follicle
stimulating hormone and testosterone by daily administration of leuprolide. J Urol 137:5760, 1987.
Maxwell F, Maxwell IH, and Glodé LM: Cloning, sequence determination, and expression
in transfected cells of the coding sequence for the tox 176 attenuated diphtheria toxin A
chain. Mol and Cell Biol 7:1576-1579, 1987.
Breitman ML, Clapoff S, Rossant J, Tsui L-C, Glodé LM, Maxwell IH, and Bernstein A:
Genetic ablation: Targeted expression of a diphtheria toxin gene causes microphthalmia
transgenic mice. Science 238:1563-1565, 1987.
Klein CE, Roberts B, Holcenberg J and Glodé LM: Cystathionine metabolism in
neuroblastoma. Cancer 62:291-296, 1988.
Manni A, Bartholomew M, Caplan R, Boucher A, Santen R, Lipton A, Harvey H,
Simmonds M, White-Hershey D, Gordon R, Rohner T, Drago J, Wettlaufer J and Glodé
LM: Androgen priming and chemotherapy in advanced prostate cancer. Evaluation of
determinants of clinical outcome. J Clin Onc 6:1456-1466, 1988.
Glodé LM, Shannon JM, Malik N, Nett T: Protection of rat spermatogenic epithelium from
damage induced by procarbazine chemotherapy. Br J Cancer 62:61-64, 1990.
Erickson PF, Maxwell IH, Su L-J, Baumann M, and Glodé LM: Sequence of cDNA for rat
cystathionine gamma lyase and comparison of deduced amino acid sequence with related
Escherichia coli enzymes. Biochemical Journal 269(2):335-340 1990.
Hemila H, Glodé LM, Palva I: Production of diphtheria toxin CRM228 in B. subtilis.
FEMS Microbiology Letters 65:193-198, 1990.
Fisher KS, Maxwell IH, Murphy JR, Collier J and Glodé LM: Construction and expression
of plasmids containing mutated diphtheria toxin A-chain-coding sequences. Infection and
Immunity 59:3562-3565, 1991.
Harrison GS, Maxwell F, Long CS, Rosen CA, Glodé LM and Maxwell IH: Activation of
a diphtheria toxin A gene by expression of human immunodeficiency virus-1 Tat and Rev
proteins in transfected cells. Human Gene Therapy 2:53-60, 1991
Maxwell IH, Glodé LM, Maxwell F: Expression of the diphtheria toxin A-chain coding
sequence under the control of promoters and enhancers from immunoglobulin genes as a
means of directing toxicity to B-lymphoid cells. Cancer Res 51: 4299-4304, 1991.
Kendall SK, Saunders TL, Long J, Ricardo V, Glodé LM, Nett TM, Keri RA, Nilson JH,
Camper SA: Targeted Ablation of Pituitary Gonadotropes in Transgenic Mice. Mol Endo
5: 2025-2036, 1991.
Mohler JL, Gomella GL, Crawford ED, Glodé LM, Zippe CD, Fair WR, Marshall EM:
Phase II evaluation of Coumarin (1,2-Benzopyrone) in metastatic prostatic carcinoma. The
Prostate 20:123-131, 1992.
7
Glodé 10/14
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
Maxwell IH, Glodé LM, Maxwell F: Expression of diphtheria toxin A-chain in mature Bcells: A potential approach to therapy of B-lymphoid malignancy. Leukemia and
Lymphoma 7: 457-462, 1992.
Harrison GS, Long CJ, Maxwell F, Glodé LM and Maxwell IH: Inhibition of HIV
production in cells containing an integrated, HIV-regulated Diphtheria toxin A chain gene.
Aids Research and Human Retroviruses 8:39-45, 1992.
Klein CE and Glodé LM: Options for preserving fertility in the chemotherapy patient.
Contemporary Oncology 48-56, 1993.
Sher CM, Crawford ED, Nabors W, Wettlaufer J, Schutz M, Davis M, Majeski S and
Glodé LM: Clinical use of FUDR in the treatment of metastatic renal cell carcinoma.
Cancer Research, Therapy and Control 4:57-60, 1994.
Cook DR, Maxwell IH, Glodé LM, Maxwell F, Stevens JO, Wagner E, Curiel DT and
Curiel TJ: Gene therapy for B-cell lymphoma in a SCID mouse model using an
immunoglobulin-regulated diphtheria toxin gene delivered by a novel adenoviruspolylysine conjugate. Cancer Biotherapy 9:131-141, 1994.
Glodé LM: The molecular bridge to gene therapy. Urology 44(6A):81-88, 1994.
Walsh P, Dorner A, Duke, Richard C., Su L-J and Glodé LM: Macrophage colonystimulating factor (M-CSF): A candidate gene for gene therapy of metastatic melanoma.
Journal National Cancer Institute 87(11):809-816, 1995.
Glodé LM: Challenges and opportunities of the internet for medical oncology. Journal of
Clinical Oncology 14(7):2181-2186, 1996.
Harrison GS and Glodé LM: Current challenges of gene therapy for prostate cancer.
Oncology 11(6):845-856, 1997.
Lidor YJ, Lee WE, Nilson JH, Maxwell IH, Su L-J, Brand E and Glodé LM: In-vitro
expression of the diphtheria toxin A-chain gene under the control of human chorionic
gonadotropin gene promoters as a means of directing toxicity to ovarian cancer cell lines.
American Journal of Obstetrics and Gynecology 177:579-585, 1997.
Reid MB and Glodé LM: Flutamide induced lupus. Journal of Urology 159:2098, 1998.
Gleave ME, Higano C, Glode LM, Goluboff E, Pummer K, and Crawford ED: New
Horizons in the Management of Hormone-Refractory Prostate Cancer. Reviews in Urology
2, 4S; 40-48, 2000.
Hardy PA, Mazzini MJ, Schweitzer C, Lundstrom K and Glodé LM: Recombinant Semliki
Forest Virus infects and kills human prostate cancer cell lines and prostatic duct epithelial
cells ex vivo. International Journal of Molecular Medicine 5:241-245, 2000.
Suh CI, Shanafelt T, May DJ, Shroyer KR, Bobak JB, Crawford ED, Miller GJ, Markham
N and Glodé LM: Comparison of telomerase activity and GSTP1 promoter methylation in
ejaculate as potential screening tests for prostate cancer. Molecular and Cellular Probes
14:211-217, 2000.
Walsh P, Gonzalez R, Dow S, Elmslie R, Potter T, Glodé LM, Baron AE, Balmer C,
Easterday K, Allen J, Rosse P: A phase I study using direct combination DNA injections
for the immunotherapy of metastatic melanoma. University of Colorado Cancer Center
Clinical Trial. Human Gene Therapy 11:1355-1368, 2000.
Vaishampayan U, Glodé M, Du W, Kraft A, Hudes G, Wright J, Hussain M. Phase II study
of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.
Clin Cancer Res 6(11):4205-4208, 2000.
Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid, E, Jegasothyu B, Wood G,
Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss, F,
8
Glodé 10/14
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
Glodé M, et al: Pivotal phase III trial of two dose levels of DAB389IL-2 (ONTAK®) for
the treatment of cutaneous T-cell lymphoma. J Clin Oncol. Jan 15;19(2):376-88, 2001.
Simmons PD, Hines S, Harrison GS, Murphy JR and Glodé LM: Internet-based survey of
physician attitudes regarding prostate cancer screening and treatment. Cancer Research,
Therapy and Control, 2001.
Mazzini MJ and Glodé LM: Internet Oncology: Increased benefit and risk for patients and
oncologists. Hematology/Oncology Clinics of North America 15(3):583-592, 2001.
Tomera K, Gleason D, Gittelman M, Moseley W, Zinner N, Murdoch M, Campion M and
Garnick M for the Abarelix Study Group: Abarelix Depot-M, a GnRH antagonist vs
leuprolide or goserelin, LHRH superagonists: Results of endocrinologic and biochemical
efficacy in patients with prostate cancer. Urology 165 (5): 1585-1589, 2001.
Crawford ED, Miller GJ, Labrie F, Hirano D, Batuello J, and Glodé LM: 11th international
prostate cancer update: Prostate cancer pathology, screening and epidemiology. Reviews
in Urology, 3 (suppl 2): S2-S10, 2001.
Goluboff ET, Hirano D, Thrasher JB, Stark G, Miller GJ, Glodé LM: New approaches to
the treatment of advanced prostate cancer. Reviews in Urology 3 (suppl 2): S69-S78, 2001.
Zinelabidine A, Miller GJ, Glodé LM, Akduman B, Donohue RE, Nedrow A, Crawford
ED: High Gleason scores and lower prostate-specific antigen levels in a single institution
over the past decade. Clinical Prostate Cancer 1(1): 2002.
Whitehead RP, Lew D, Flanigan RC, Weiss GR, Roy V, Roy V, Glodé LM, Dakhil SR and
Crawford ED: Phase II trial of recombinant human interleukin-4 in patients with advanced
renal cell carcinoma: A Southwest Oncology Group study. Journal of Immunotherapy
25(4):352-358, 2002.
Abouelfadel Z, Miller GJ, Glodé LM, Akduman B, Donohue R, Nedrow A, Crawford ED:
High Gleason scores and lower prostate-specific antigen levels in a single insitution over
the past decade. Clinical Prostate Cancer Vol 1, 1(4): 115-117, 2002.
Bergen M, Lewis K, Chen R, Kenney T, Glodé LM: Prostate cancer on the internet:
impact on patients and how technology helps physicians and researchers. Clinical Prostate
Cancer 1(4): 227-234, 2003.
Dhanalakshmi S, Agarwal P, Glodé LM and Agarwal R: Silibinin sensitizes human
prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and
apoptotic death. Journal of Cancer 106: 699-705, 2003.
Glodé LM, Barqawi A, Crighton F, Crawford ED, and Kerbel R: Metronomic therapy with
cyclophosphamide and dexamethasone for prostate cancer. Cancer 98 (8): 1643-1648,
2003.
Skinner EC and Glodé LM: High risk localized prostate cancer: Primary surgery and
adjuvant therapy. Urologic Oncology 21(3): 219-227, 2003.
Qi L, Singh RP, LU Y, Agarwal R, Harrison GS, Franzusoff A, and Glodé LM: Epidermal
growth factor receptor mediates silibinin-induced cytotoxicity in a rat glioma cell line.
Cancer Biology and Therapy 2(5):526-531, 2003.
Qi L, Nett TM, Allen MC, Sha X, Harrison GS, Frederick BA, and Glodé LM: GnRH –
PAP hormonotoxin targets cytotoxicity to prostate cancer cell lines. Urological Research
31 (6): 374-377, 2003.
Qi L, Robinson WA, Brady BMR, Singh R, and Glodé LM: Relationship between
expression of VEGF and its receptors to migration and invasion of human prostate cancer
cells in vitro. Anticancer Research 23(5A): 3917-22, 2003.
9
Glodé 10/14
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
Tyagi AK, Agarwal C, Singh RP, Shroyer KR, Glodé LM,and Agarwal R: Silibinin downregulates survivin protein and mRNA expression and causes caspases activation and
apoptosis in human bladder transitional-cell papilloma RT4 cells. Biochemical and
Biophysical Research Communications 312: 1178-1184, 2003.
Qi L, Nett TM, Allen MC, Sha X, Harrison GS, Frederick BA, Crawford ED, and Glodé
LM: Binding and cytotoxicity of conjugated and recombinant fusion proteins targeted to
the GnRH receptor. Cancer Research 64: 2090-2095, 2004.
Fung KY, Glodé LM, Green S, and Duncan M: A comprehensive characterization of the
peptide and protein constitutents of human seminal fluid. The Prostate 61(2): 171-181,
2004.
Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, Rosenblum M,
Kane M, Chen L, and Crawford ED: The use of trastuzumab in the treatment of hormone
refractory prostate cancer; phase II trial.
Prostate. 60(4): 332-337, 2004.
Tyagi A, Agarwal C, Harrison G, Glodé LM, and Agarwal R: Silibinin causes cell cycle
arrest in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin
cascade, and caspase 3 and PARP cleavages. Carcinogenesis 12(9): 1711-1720, 2004.
Harrison GS, Wierman MA, Nett TM, and Glodé LM: GnRH and its receptor in normal
and malignant cells. Endocr. Related Cancer 11: 725-748, 2004.
Yang W-H, Allen MC, Wieczorek M, Glodé LM, and Nett TM: A sandwich enzyme-linked
immunoabsorbent assay for measurement of gonadotropin-releasing hormone toxin, Amer
J. Reprod. Immunol. 55: 208-216, 2006.
L.M. Glode and M. Lindquist: The case for adjuvant therapy of prostate cancer, Prostate
Cancer Supplement, J. Urol. S30-3, 2006.
Denberg T, Glode M, Steiner J, Crawford D, Hoffman R: Trends and predictors of
aggressive therapy for clinical locally advanced prostate carcinoma. BJU International
10.111, 2006.
Grossman HB, Tangen CM, Cordon-Cardo C, Cote R, Waldman FM, De Vere White RW,
Karnad AB, Glode M, and Crawford ED: Evaluation of Ki67, p53 and angiogenesis in
patients enrolled in a randomized study of neoadjuvant chemotherapy with or without
cystectomy: a Southwest Oncology Group Study. Oncol. Rep. 16(4): 807-810, 2006.
Flaig TW, Barqawi A, Miller G, Kane M, Zeng C, Crawford ED, and Glodé LM: A phase
II trial of dexamethasone, vitamin D and carboplatin in patients with hormone refractory
prostate cancer. Cancer 107(2):266-274, 2006.
Flaig TW, Nordeen SK, Lucia S, Harrison G, and Glodé LM.: Conference Report: Current
status of biomarkers potentially associated with prostate cancer outcomes. J. Urol,
Apr;177(4):1229-37, 2007.
Flaig TW, Su Lih-Jen, Agarwal R, and Glodé LM: Silibin synergizes with mitoxantrone to
inhibit cell growth via apoptosis in prostate cancer cells. Int. J. Cancer May 1;120(9):
2028-33, 2007.
Flaig TW, Gustafson DL, Su L, Zirrolli J, Harrison G, Pierson AS, Agarwal R, and Glodé
LM: A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer.
Investigational New Drugs Apr;25(2):139-46. Epub 2006 Nov 1, 2007.
Arthur C, Flaig T, Su L, Denney R, Barnes F, and Glodé LM: The effect of ultrasonic
irradiation on adriamycin-induced cytotoxicity in three human bladder cancer cell lines.
Ultrasonics Mar;46(1):68-73. Epub 2006 Nov 27, 2007.
M. Hussain, G. R. MacVicar, D. Petrylak, R. Dunn, U. Vaishampayan, P.N. Lara, Jr, G.
Chatta, D. Nanus, L.M. Glode, D. Trump, H. Chen, and D.C. Smith: Trastuzumab,
10
Glodé 10/14
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
Paclitaxel, Carboplatin, and Gemcitabine In Advanced Her-2/neu Positive Urothelial
Carcinoma: Results of a Multi-Center Phase II NCI Trial. J. Clin. Oncol., Jun 1:25(16):
2218-24, 2007.
Tyagi A, Raina K, Singh RP, Gu M, Agarwal C, Harrison G, Glode LM, and Agarwal R:
Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl)
nitrosamine induced urinary bladder carcinogenesis in male ICR mice .Mol Cancer Ther.,
Dec;6(12):3248-55, 2007.
Raina K, Blouin MJ, Singh RP, Majeed N, Deep G, Varghese L, Glodé LM, Greenberg
NM, Hwang D, Cohen P, Pollak MN, and Agarwal R.:Dietary feeding of silibinin inhibits
prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate
model. Cancer Res, Nov 15;67(22):11083-91, 2007
Flaig T, Crawford ED, Kavanagh B, Lucia S, La Rosa F, Barqawi A, Crighton F and Glodé
LM.: Prostate cancer in a man with multiple previous cancers, Oncology (Williston Park),
Apr;21(5):611-4, 2007.
Flaig TW, Tangen CM, Hussain MH, Stadler WM, Raghavan D, Crawford ED, Glode
LM: Randomization reveals unexpected acute leukemias in Southwest Oncology Group
prostate cancer trial. J Clin Oncol, Mar 20:26(9):1532-36, 2007.
Glode LM, Metabolic syndrome and prostate cancer. Cancer, May 15;112(10):2188-94,
2008.
Attia S, Eickhoff J, Wilding G, McNeel D, Blank J, Ahuja H, Jumonville A, Eastman M,
Shevrin D, Glode M, Alberti D, Staab MJ, Horvath D, Straus J, Marnocha R, Liu G:
Randomized, double-blinded phase II evaluation of docetaxel with or without
doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin
Cancer Res Apr 15;14(8):2437-43, 2008.
Flaig TW, Glode LM.: Management of the side effects of androgen deprivation therapy in
men with prostate cancer. Expert Opin Pharmacother. Nov;9(16):2829-41, 2008.
Flaig TW, Glodé LM, Gustafson D, Van Bokhoven A, Tao Y, Yuzhen T, Wilson S, Su L-J,
Yuan L, Harrison G, Agarwal R, Crawford ED, Lucia S, Pollak M: A Pilot Study of HighDose Oral Silybin-Phytosome Followed by Prostatectomy in Patients with Localized
Prostate Cancer. The Prostate, Jun 1;70(8): 848-55, 2010.
Kantoff PW, Schuetz TJ, Blumenstein BA, Glodé LM, Bilhartz DL, Wyand SM, Manson
K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley J, Godfrey WR: Overall
survival (OS) analysis of a Phase II randomized controlled trial (RCT) of a poxviral-based
PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC).
Journal Clinical Oncoglogy. Mar 1;28(7): 1099-105, 2010.
Stinauer MA, Kavanagh BD, Schefter TE, Gonzalez R, Flaig T, Lewis K, Robinson W,
Chidel M, Glode M, Raben D: Stereotactic body radiation therapy for melanoma and renal
cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol.
Apr 8; 6:34, 2011
Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP Jr, Sakr WA,
Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM: Adjuvant
androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG
S9921 study. J Clin Oncol. May 20;29(15):2040-5. Epub 2011 Apr 18, 2011.
Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, Schellhammer PF,
Jones LA, Xu Y, Kylstra JW, Frohlich M: Randomized Trial of Autologous Cellular
Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer. Clin Cancer
Res. Jul 1;17(13):4558-4567, 2011.
11
Glodé 10/14
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
Clemons J, Glodé LM, Gao D, Flaig TW: Low-dose diethylstilbestrol for the treatment of
advanced prostate cancer. Urol Oncol. Jul 25. [Epub ahead of print], 2011.
Wilson SS and Glode, LM. Appropriate use of Androgen Deprivation Therapy in the
Treatment of Prostate Cancer in the Modern Era. AUA Update Series, 2011 (submitted).
Werahera PN, Glode LM, La Rosa FG, Lucia MS, Crawford ED, Easterday K, Sullivan H,
Sidhu RS, Genova E, Hedlund T: Proliferative tumor doubling times of prostatic
carcinoma. Prostate Cancer, Vol. 2011, Art.301850, 2011. Doi:10.115/2011/301850.
Lam ET, La Rosa FG,Suby-Long TD, Kondo KL, Wilson S, Glode LM, Flaig TW: A rare
case of metastatic renal epithelioid angiomyolipoma. Oncology Aug;25(9):832-8, 2011.
Amato RJ, Glode LM, Podolnick J, Knight R, Crawford ED: Phase II study of
pomalidomide in patients with castration-resistant prostate cancer. Cancers, (3)3449-60,
2011.
Marsland T, Arena F, Yeilding A, Glodé M, Ellis L, Yu J, Henderson C, Wagman L, Piver
S, Minsky B, Rosen S, Poplack D, Potters L, Crawford D, Hoskins W: Perspective on...the
new PSA screening recommendations. Oncology, 2011 Nov 15;25(12):1183, 1187-8, 1190.
Chaudhry A, Glodé LM, Gillman M, Miller RS: Trends in twitter use by physicians at the
american society of clinical oncology annual meeting, 2010 and 2011. J Oncol Pract. 2012
May;8(3):173-8. Epub 2012 Apr 17.
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, Flaig TW, Affirm
Investigators- Glode LM: Increased survival with enzalutamide in prostate cancer after
chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187-97. Epub 2012 Aug 15.
Xiaoping Yang1,7, Lih-Jen Su1,7, Andrew Thorburn2,7, Arthur E. Frankel3, Yuan Li1, 4,
Francisco G. La Rosa5,7, Elizabeth Kessler1, Jingping Shen6,7, Chuan-Yuan Li6,7, Marileila
Varella-Garcia1,7, L. Michael Glodé1,7, Thomas W. Flaig: Diphtheria Toxin-Epidermal
Growth Factor Fusion Protein DAB389EGF for the treatment of bladder cancer. Clin Cancer
Res. 2013 Jan 1;19(1):148-57.
Lam ET, Glode LM: Neoadjuvant and adjuvant hormonal and chemotherapy for prostate
cancer. Hematology Oncology Clinics of North America. 2013 Dec;27(6):1189-204.
Glode LM, Lam ET: Nonseminomatous germ cell tumor of testis and interrupted
treatment. Oncology. 2013 Aug;27(8):822-3.
Beer TM, Schellhammer PF, Corman JM, Glode LM, Hall SJ, Whitmore JB, Frohlich MW,
Penson DF: Quality of life after sipuleucel-T therapy: results from a randomized, doubleblind study in patients with androgen-dependent prostate cancer. Urology. 2013
Aug;82(2):410-5.
Dorff TB, Glode LM: Current role of neoadjuvant and adjuvant systemic therapy for highrisk localized prostate cancer. Curr. Opinion Urology. 2013 Jul;23(4):366-71.
Lam, E, Glode, LM: Neoadjuvant and adjuvant hormonal and chemotherapy for prostate
cancer. Hematology Oncology Clinics of North America. 2013, 27:1189-1204
Schlaepfer I, Rider, L, Rodrigues L, Gijon M, Pac C, Romero L, Cimic A, Sirintrapun S,
Glode LM, Eckel R, Cramer S: Lipid Catabolism via CPT1 as a Therapeutic Target for
Prostate Cancer. Molecular Cancer Therapies. 2014, 13;2361.
Shah K, Sciotto C, Glode LM, Robinson W: A Family with Mastocytosis, Achalasia, GIST
Tumors and a Unique Mutation in KIT. Submitted.
Letters
12
Glodé 10/14
1.
2.
3.
4.
5.
Glodé LM: "Gonadal Activity and Chemotherapy-Induced Gonadal Damage." JAMA:
Letter #LE8149. 260(14):2064-2065, 1988.
Glodé LM: Prostate Cancer Screening. A place for informed consent? Hospital Practice,
Editorial, 29(9):8-12, 1994.
Glodé LM: PalmPiloting through my life. Oncology Times, page 28, November 2000.
Glodé LM: Adjuvant therapy may improve PCa survival outcomes. Urology Times
32(7): 24-25, 2004.
Eisenberger M and Glodé LM: Case Reports on Prostate Cancer. Invited Letter Reviews
in Urology, 6 (Suppl 7) S39-S45, 2004.
Book Chapters
1.
Glodé LM: Cytotoxic and immunosuppressive drugs. In: Clinical Use of Drugs in Patients
with Kidney and Liver Disease. Anderson, R. and Schrier, R. (eds). W.B. Saunders Co.,
Philadelphia, PA, pp.260-275, 1981.
2.
Robinson WA, Glodé LM: Medical Oncology in Clinical Internal Medicine. Reller, B.,
Sahn, S., Schrier, S. (eds). 2nd Edition, Little, Brown & Co., Boston, 1982.
3.
Glodé LM: Gonadotropin-releasing hormone analogues and other new hormonal
treatments of prostate cancer. In: Contemporary Issues in Clinical Oncology, Vol. 5,
Genitourinary Cancer, Garnick MB, ed., Churchill Livingston, pp 105-124, 1985.
4.
Santen R, English H, Rohner T, Drago J, Lipton A, Harvey H, Simmonds M, Boucher A,
Glodé LM, Wettlaufer J, Gordon R and Manni A: Androgen depletion/repletion in
combination with chemotherapy: Strategy for secondary treatment of metastatic prostatic
cancer. In: European Organization for Research on Treatment of Cancer Monograph No.
2, Alan R. Liss, Inc., New York (F.H. Schroeder, Ed.), pp. 359-371, 1985.
5.
Glodé LM: Hodgkin's disease. In: Surgical Secrets. Abernathy C, Abernathy B (eds).
Hanley & Belfus Inc., Philadelphia, PA, pp. 190-192, 1986.
6.
Manni A, Santen RJ, Boucher AE, Lipton A, Harvey HA, Simmonds MA, White-Hershey
D, Gordon RA, Rohner TJ, Drago J, Wettlaufer J, Glodé LM: Androgen priming and
chemotherapy in the treatment of advanced prostate cancer. In: New Trends in Diagnosis
and Treatment of Prostatic Cancer. Edizioni and Congressi (eds). Acta Medica, p. 235240, 1987.
7.
Garnick MB, Lipton A, Max DT, Smith JA, Harvey HA and Glodé LM: Trials with
Leuprolide. In: LHRH and its analogs. Contraceptive and theuapeutic applications. Part
2. Boston, MA MTT press ltd., pp. 384-395, 1987.
8.
Glodé LM and Scapdino PT: Prostatic carcinoma. In Diseases of the Kidney, Fourth
Edition. Schrier, RE and Gottsohalk CW, eds., pp 921-937, 1988.
9.
Maxwell IH, Glodé LM, Maxwell F, Harrison GS, Breitman ML, Rombola H, Coulson DM and Bernstein A: Targeted cell suicide by toxin gene expression. In Gene Transfer and
Gene Therapy. Alan R. Liss, pp. 189-204,1989.
10.
Klein CE, and Glodé LM: Gonadal Complications. In: High-Dose Cancer Therapy.
Pharmacology, Hematopoietins, Stem Cells. JO Armitage and KH Antman, eds. Williams
and Wilkins, Baltimore, MD, pp 555-568, 1992.
11.
Glodé LM, and Klein CE: Complications of cancer and its treatment. Gonadal
complications. Cancer Medicine 3rd Edition, Holland JF Frey E, Bast RC, et al (eds). Lea
and Febiger, 1992.
12.
Glodé LM: Prostatic carcinoma. In Diseases of the Kidney, Fifth Edition. Schrier RE and
Gottsohalk CW, eds., pp 921-937, 1992.
13.
Klein CE and Glodé LM: Protection of gonadal function. Oncology Times, 1993.
13
Glodé 10/14
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
Klein CE and Glodé LM: Options for preserving fertility in the chemotherapy patient.
Contemporary Oncology, pp 48-56, 1993.
Glodé LM and Holm C: Prostate. Current Therapy in Cancer, Foley JF, Vose JM and
Armitage JO, eds, pp 140-146, 1994.
Klein CE and Glodé LM: Options for preserving fertility in the chemotherapy patient.
Contemporary Urology, pp 48-56, 1995.
Glodé LM: Spirituality in Medical Oncology. American Society of Clinical Oncology
Education Book, page 66, 1996.
Glodé LM: Cancer information on the world wide web. American Society of Clinical
Oncology Education Book, pages 29-33, 1997.
Glodé LM and Crawford ED: Prostatic carcinoma. In RW Schrier and CW Gottschalk
(eds) Diseases of the Kidney, Sixth Edition. Little, Brown, pages 823-838, 1997.
Glodé LM and Petrylak DP: Refractory disease, new horizons and patient-physician
relationships. In MK Brawer (ed) Prostate Cancer and Prostatic Diseases. Stockton Press,
5:1-2, 1998.
Glodé LM: Early prostate cancer diagnosis and therapy. In RW Schrier, JD Baxter, VJ
Dzau, AS Fauci (eds) Advances in Internal Medicine, vol 45. Mosby Inc, pages 41-64,
2000.
Glodé LM, Crawford ED, Gleave ME: Prostatic carcinoma. In RW Schrier and CW
Gottschalk (eds) Diseases of the Kidney, Seventh Edition. Lippincott Williams & Wilkins,
2001.
Glodé LM: Clinical trials in practice. IN JS Silva, MJ Ball, CG Chute, JV Douglas, CP
Langlotz, JC Niland, WL Scherlis (eds) Cancer Informatics: Essential Technologies for
Clinical Trials. Springer-Verlag, pp 33-43, 2002.
Glode LM, Pierson AS, Barqawi AB, Flaig T. Prostate Cancer Diagnosis, Risk
Assessment and Management (2 hours of AMA CME). On-line publication: January 19,
2005 (3rd version). www.vlh.com (The Virtual Lecture Hall).
Harris S and Glodé LM: Informatics in medical education.
Wilson SS, Crawford ED, Glodé LM: Prostatic carcinoma. In RW Schrier and CW
Gottschalk (eds) Diseases of the Kidney, Eighth Edition. Lippincott Williams & Wilkins,
2006.
Karp D, Blum R, Hudism C, Glode M, Snijders A; Antigen presenting cell activation in
sipuleucel-T and long-term immune responses in prostate cancer trial. ASCO Ed Book,
2009.
Lam ET, Glode LM; Management of locally advanced prostate cancer. Handbook of
Urology, Second Edition, Chapter 21.9, 2011.
Sweeney CJ, Canellos GP, Bunn HF, Glode LM, et.al.: Clinics Review Articles
Hematology/Oncology Clinics of North America – Prostate Cancer. Vol. 27, Num.6, Dec.
2013.
Abstracts
1.
Glodé LM, Scher I, and Rosenstreich DL: Endotoxin unresponsiveness in C3H/HeJ mice.
Fed Proc 34:951, 1975.
2.
Glodé LM: Genetic control of endotoxin responses in mice. Fed Proc 35:824, 1976.
3.
Ryan J, Glodé LM, and Nathan C: LPS induced glucose utilization in C3H/HeN and
C3H/HeJ macrophages. Fed. Proc. 36:1263, 1977.
4.
Glodé LM, Israel M, Pegg WJ, and Wilkinson PM: Hepatobiliary metabolism and
excretion of adriamycin in man. Proc Brit Pharmacol Soc, p. 35, 1977.
14
Glodé 10/14
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
Garnick MB, Israel M, Ensminger WD, and Glodé LM: Pharmocological advantages of
adriamycin via intrahepatic arterial infusion. Proc Amer Assoc Cancer Res 19:400, 1978.
Glodé LM, Pitman SW, and Frei E III: Phase I study of high dose aminopterin with
citrovorum factor rescue. Proc AACR and ASCO 19:634, 1978.
Corkery JC, Glodé LM, Whipple C, McIntosh EN, Holtrop HR, and Salhanick HA:
Inhibition of peripheral aromatization by aminoglutethimide. Proc Amer Assoc. Cancer
Res 20:233, 1979.
Glodé LM, Hartmann DW, and Robinson WA: The acute and cumulative marrow toxicity
of chemotherapy in small cell carcinoma of the lung with and without bone marrow
support. Proc Amer Soc Clin Onc 21:448, 1980.
Glodé LM, Epstein AL, and Smith CG: Reduction in the amount of cystathionase
contained in human leukemic cell lines as determined by quantitative
radioimmunoelectrophoresis using a monoclonal hybridoma antibody. Proc Amer Assoc
Cancer Res 21:11, 1980.
Glodé LM, Epstein AL, Smith C, and Robinson WA: Cystathionase: Measurement by
radioimmunoelectrophoretic assay using hybridoma antibody and its potential use as a
marker of leukocyte differentiation. Clinical Res 28:525A, 1980.
Robinson JI, Gould SF, Glodé LM, and Robinson WA: Protection from
cyclosphosphamide induced testicular damage by an analogue of gonadotropin releasing
hormone. Proc of Am Fed Clin Res meeting, Feb. 198l.
Harvey HA, Lipton A, Santen RJ, Escher GC, Hardy MA, Glodé LM, Segaloff A, Landau
RL, Schneir H, and Max DT: Phase II study of a gonadotropin-releasing hormone
analogue (Leuprolide) in postmenopausal advanced breast cancer patients. Proc ASCO
22:444, 1981.
Schneir HE, Landau RL, Max D, Harvey HA, Lipton A, Santen RJ, Escher GC, Hardy MA,
Glodé LM, and Segaloff A: The endocrine effects of chronic treatment with a
gonadotropin releasing hormone (GnRH) analogue. Endocrine Society, 1981.
Warner B, Santen R, Demers L, Max D, Lohmar P, Smith J, Muss H, Resnick M, Glodé
LM, Wettlaufer J, Eisenberger M, and Block N: Effects of [D-Leu-6-Des-Gly-NH2 10,
Pro-ethylamide9]-GnRH (Leuprolide) on steroidogenesis when used to treat prostatic
carcinoma. Am Soc of Andrology 3(1):14, 1982.
Dantas ME, Robinson WA, Thomas MR, Koeppler H, and Glodé LM: Autologous
marrow infusion in blastic crisis of chronic myeloid leukemia. Blood 58 (5)(Suppl.
1):172a, 1981.
Link D, Glodé LM, Drebing C: Cystathionase--A new marker of leukemic differentiation.
Blood 58(5)(Suppl. 1):145a, 1981.
Glodé LM, Gould SF, Nett T, and Powell D: A rat model for MOPP induced male
infertility. Proc of Am Assoc Cancer Res 23:222, 1982.
Glodé LM: Leuprolide therapy of advanced prostatic cancer. Proc of Am Soc Clin Onc
1:110, 1982.
Rifkin JI, Horwitz LD, Glodé LM: Hypothermic modulation of cutaneous and testicular
vascular resistance. Am Fed Clin Res (Western), February, 1983.
Smith H, Geyer M, Stears J, Kindt G, Glodé L.M: Intra-carotid BCNU in the treatment of
malignant brain tumors. A phase I trial. Am Fed Clin Res (Western), February, 1983.
Thomas MR, Robinson WA, Dantas M, Koeppler H, Glodé LM, Drebing C: Autologous
bone marrow transplantation in chronic mylogenous leukemia (CML) in blast crisis. Am
Fed Clin Res (Western), February, 1983.
15
Glodé 10/14
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
Thomas MR, Robinson WA, Glodé LM, Koeppler H, Dantas M, Morton N: Treatment of
advanced malignant melanoma with high dose BCNU and melphalan and autologous bone
marrow transplantation - preliminary results phase I. Am Fed Clin Res (Western),
February, 1983.
Thomas MR, Robinson WA, Mughal T, Morton N, Glodé LM, and Garfield D: Autologous
bone marrow transplantation and high dose chemotherapy in advanced malignant
melanoma phase 1 study. Proc Am Soc Clin Onc 2:243, 1983.
Klein CE, Glodé LM, and Helson C: Cystathionase expression in human neuroblastoma
(N) cell lines. Proc Am Assoc Cancer Res 24:40, 1983.
Chitambar CR, Glodé LM, Robinson WA, and Lehman J: Low dose 5-azacytidine therapy
in leukemia. Proc Am Assoc Cancer Res 24:299, 1983.
Glodé LM, Robinson WA, Hartmann DH, and Morton N: Pharmacokinetics of high dose
combination therapy using a CFU-c bioassay. Proc Am Soc Clin Onc 2:24, 1983.
Geier JM, Smith H, Braun T, Gross C, Kindt G, and Glodé LM: Extracerebral toxicity of
continuous intracarotid FUDR via implanted infusaid pump in brain tumor patients. Surg
Forum, 1983.
Glodé LM, Max D, and the Takeda-Abbott Prostatic Cancer Study Group: Leu prolide (Dleu6-Des Gly10-Pro9-NH et-LHRH) in the therapy of advanced prostatic carcinoma. 13th
International Congress of Chemotherapy 242:49-53, 1983.
Shannon JM and Glodé LM: Demonstration of direct effects of [d-leu6, pro9- NEt]LHRH
(Leuprolide) in the rat testis in vivo. Presented at 8th NICHd Inter national Workshop on
the Testis, October 14-17, 1983, Bethesda, Maryland.
Shannon JM, and Glodé LM: Cultivation of sertoli cells on floating collagen gels: An
improved method for studying cell-cell interactions in vitro. Presented at 8th NICHD
International Workshop on the Testis, October 14-17, 1983, Bethesda, Maryland.
Mughal TI, Glodé LM, Braun TJ, Geyer M, and Kindt G: Phase I study of intra-arterial
Bis-chloroethyl nitrosourea and 2'-deoxy-5-fluorouridine in malignant astrocytomas.
Presented at the 75th Annual Meeting of the American Association for Cancer Research,
May 10, 1984.
Manni A, Santen RJ, Boucher A, Lipton A, Harvey H, White D, Simmonds M, Rohner T,
Drago J, Wettlaufer J, and Glodé LM: Aminoglutethemide and chemotherapy with and
without transient androgen administration in the treatment of advanced prostate cancer.
Proc Amer Soc Clin Onc 3:152, 1984.
Glodé LM, and Smith CG: Evaluation of cysteine analogues as cytotoxins in cysteine
auxotrophic/prototrophic cell lines. Proc Amer Assoc Cancer Res 1984.
Mughal TI, Robinson WA, Thomas MR and Glodé LM: Malignant melanoma and BCNU.
Clin Onc 10:185, 1984.
Glodé LM: Long-term safety of the GnRH analogue, Leuprolide (Lupron, Leu) vs.
Diethylstilbesterol (DES) in metastatic prostate cancer--An update. 14th International
Congress of Chemotherapy, 1985.
Glodé LM: Mode of action and therapeutic potential of the LHRH agonist, Leuprolide.
14th International Congress of Chemotherapy, 1985.
Glodé LM: Long-term toxicity of the GnRH analogue, Leuprolide (Lupron, LEU) vs.
Diethylstilbesterol (DES) in metastatic prostate cancer - An up date: Part II. Amer Soc Clin
Onc, 1985.
Glodé LM, Shannon JM, Nett TM, and Carl VS: Differences in the effects of a GnRH
agonist on human and rodent spermatogenesis. Am Fed Clin Res, 1985.
16
Glodé 10/14
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
Manni A, Santen RJ, Boucher A, Lipton A, Harvey H, White D, Simmonds M, Gordon R,
Rohner T, Drago J, Wettlaufer J, and Glodé LM: Potentiation of the effect of
chemotherapy in stage D2 prostate cancer by transient androgen administration. Proc
ASCO, 1985.
Maxwell IH, Maxwell F, Glodé LM: Regulated expression of transfected toxin genes - A
potential new therapeutic strategy. Proc. AACR, 1986. Inter Cong of Chemotherapy,
Kyoto, Japan, 1985.
Manni A, Santen R, Boucher A, Lipton A, Harvey H, White D, Simmonds M, Gordon R,
Rohner T, Drago J, Wettlaufer J, and Glodé LM: Androgen priming and response to
chemotherapy in advanced prostate cancer. Presented: Pennsylvania Oncologic Society
Annual Meeting, September 12-13, 1986, Hershey, Pennsylvania.
Manni A, Santen R, Boucher A, Lipton A, Harvey H, White D, Simmonds M, Gordon R,
Rohner T, Drago J, Wettlaufer J, and Glodé LM: Androgen priming and chemotherapy in
advanced prostate cancer. Presented: 1st International Symposium on Advances in
Urologic Oncology, Sanremo, Italy January 22-24, 1987.
Manni A, Santen R, Boucher A, Lipton A, Harvey H, White D, Simmonds M, Gordon R,
Rohner T, Drago J, Wettlaufer J, and Glodé LM: Androgen priming and chemotherapy in
advanced prostate cancer. Proc ASCO, 1987.
Klein C, Glodé LM: Brain Metastases in Malignant melanoma: Risk factors, routines of
spread and outcome. Proc ASCO, 1987.
Manni A, Santen R, Boucher A, Lipton A, Harvey H, White D, Simmonds M, Gordon R,
Rohner T, Drago J, Wettlaufer J, Glodé LM: Androgen priming and chemotherapy in
advanced prostate cancer. Presented: Intl. Symposium on Hormonal Therapy of Prostatic
Disease, Milano, Italy, 1987.
Glodé LM, Maxwell IH, Maxwell F, Sitarik M, Kallio A, Ulmanen I: Regulated
Expression of a Transfected Diphtheria Toxin A-Chain Gene as a Novel Mechanism for
Eliminating Specific Target Cell Populations. Presented: XVII Linderstrom-Lang
Conference on Receptor Effector Mechanisms and Gene Regulation, Geilo, Norway, April
26-30, 1987.
Manni A, Santen RJ, Boucher AE, Lipton A, Harvey HA, Simmonds MA, White-Hershey
D, Gordon RA, Rohner TJ, Drago J, Wettlaufer J, Glodé LM: Androgen priming and
chemotherapy in the treatment of advanced prostate cancer. Proc of Intl Symp on Hormon
TX of Prost Dis, Medic (UK)Inc. (In press) 1987.
Glodé LM, Maxwell IH, Maxwell F, Sitarik M, Kallio A, Ulmanen I: Regulated
Expression of a Transfected Diphtheria Toxin A-Chain Gene as a Novel Mechanism for
Eliminating Specific Target Cell Populations. Presented: European Assoc Cancer Research,
Helsinki, Finland, June 1987.
Maxwell IH, Glodé LM, Maxwell F: HTLV-regulated expression of a transfected diptheria
toxin gene. Presented at Human retroviruses, cancer and AIDS meeting, April 1-6, 1987.
Manni A, Santen R, Boucher A, Lipton A, Harvey H, Simmonds M, White-Hershey D,
Bartholomew M, Caplan R, Gordon R, Rohner T, Drago J, Wettlaufer J, Glodé LM: Novel
approaches to the treatment of advanced prostate cancer. 1988.
Manni A, Bartholomew M, Caplan R, Boucher A, Santen R, Lipton A, Harvey H,
Simmonds M, White-Hershey D, Gordon R, Rohner T, Drago J, Wettlaufer J, Glodé LM:
Androgen priming and chemotherapy in advanced prostate cancer. Evaluation of
determinants of clinical outcome. 1988.
17
Glodé 10/14
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
Glodé LM, Maxwell IH, Maxwell F, Sitarik M, Kallio A, Ulmanen I: Regulated
expression of a transfected diptheria toxin gene as a novel mechanism for killing tumor
cells. J Cellular Biochem Suppl 12B, 1988.
Maxwell IH, Glodé LM, Maxwell F: Diphtheria toxin A-chain expression directed to Blymphoid cells. J Cellular Biochem Suppl 12B, 1988.
Manni A, Bartholomew M, Caplan R, Boucher A, Santen R, Lipton A, Harvey H,
Simmonds M, White D, Gordon R, Rohner T, Drago J, Wettlaufer J, and Glodé LM:
Determinants of biologic behavior in advanced prostate cancer. Proc ASCO 1988.
Fisher KS, Maxwell IH, Glodé LM: Expression of mutant diphtheria toxin A-chain
expression plasmids in eukaryotic cells. Proc AACR 30:627, 1989.
Glodé LM, Su L-J, Maxwell F, Maxwell IH, and Nilson J: Toward toxin gene therapy of
cancer. Use of a and b HCG promoters to regulate expression of diphtheria toxin A-chain
(DT-A) in model target cells. Proc AACR 30:627, 1989.
Su L-J, Maxwell IH, Harrison GS, Glodé LM: Assay of retrovirus infectivity by
transduction of luciferase. Proc AACR 32:299, 1991.
Glodé LM, The Leuprolide Study Group: Long term evaluation of leuprolide versus DES
treatment for prostate cancer. Proc ASCO 1991.
Yu NY, Kaleta-Michaels SJ, Singh SS, Luck EE, and Brown DM, Menlo Park, CA;
Daneshi-Gari F, and Glodé LM: Intraprostatic Therapeutic Implant Provides Sustained
Drug Release in Rate Prostate. August, 1992.
Lidor YJ, Maxwell IH, Feldman I, Brand E, Glodé LM: Generation of a New Therapeutic
Retroviral Vector, pLNX-TH47R, for Toxin Gene Therapy in Ovarian Cancer. November
1992.
Walsh P, Duke RC, Schleicher M, Dorner A, and Glodé LM: Assessment of the cellular
immune response to a macrophage colony stimulating factor producing melanoma cell line.
October 1993.
DeAntoni EP, Dyer BA, Glodé LM, and Kogel C: Knowledge, attitudes and health
behaviors among participants in a prostate cancer screening program. 1993.
Glodé LM, Crawford ED, Majeski S, Schmidt R, Cook S and Murphy J: Sinusoidal
floxuridine (FUDR) infusions for treatment of advanced hormone refractory prostate
cancer. PROC ASCO, 1994.
Dumont FD, Su LJ and Glodé LM: Intact cell luciferase assay as a rapid tumor sensitivity
test. PROC AACR 35:1221, 1994.
Walsh P, Dorner A and Glodé LM: Gene therapy for melanoma using M-CSF and the
B16F10 cell line. Gene Therapy, 1994.
Klein CE, Prochazka A, Spitzer AL, Gordon B, Glodé LM: Spousal report of quality of
life in treatment for localized prostate cancer. ASCO Annual Meeting, May 18-21, 1996.
Lee WE, Gorman C, Roche L, Michaud B, Su LJ, Tomczak JA, Glodé LM. In vivo
delivery of foreign genes by liposomes into an ovarian cancer animal model. ASCO
Annual Meeting, May 18-21, 1996.
May DJ, Shroyer, K, Glodé LM: Detection of Telomerase activity in immortal prostate
cancer cell lines in peripheral blood samples. American Urological Association, Inc,
September 7-11, 1996.
Shroyer KR, May DJ, Cutler W, Markham N and Glodé LM: Prostate cancer screening by
telomerase assay of seminal fluid. ASCO Annual Meeting, May 17-21, 1997.
Bacha P, Fowlie A, Grimaldo D, Hillier J, Olsen E, Martin A, Kim Y, Duvic M, Frankel A,
Vonderheid E, Bowen G, Jegasothy B, Wood, G, Gordon M, Pinter-Brown L, Fivenson D,
Heald P, Oseroff A, Kuzel T, Foss F, Glodé M, Stewart S, Molina A, Knobler B: Antibody
18
Glodé 10/14
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
and pharmacokinetic analysis from a pivotal trial of DAB389 IL-2 for the treatment of
cutaneous T-cell lymphoma (CTCL). Presented at the American Society of Hematology
annual meeting, December 4-9, 1997.
Kuzel T, Olsen E, Martin A, Kim Y, Davis M, Frankel A, Vonderheid E, Bowen G,
Jegasothy B, Wood G, Gordon M, Pinter-Brown L, Fivenson D, Heald P, Oseroff A, Foss
F, Glodé M, Stewart S, Molina A, Knobler B, Nichols J: Phase III trials of two dose levels
of a diptheria toxin (DT) fusion protein (DAB389 IL-2) for the treatment of mycosis
fungoides (MF/SS). Presented at American Society of Hematology annual meeting,
December 4-9, 1997.
Garnick MB, Wierman M, Kuca B, Joyce R, Martin K, O’Hagen P, Glodé LM, Gefter M:
The “acute on chronic” phenomenon - a manifestation of inadequate gonadotropin
suppression - is common with currently available LHRH superagonists. Presented at the
American Urologic Association, May 1-6, 1999.
Menon M, Glodé LM, Martin K, McLeod D, Cohen S, Steadman B, Molineaux C, Gefter
ML, Kuca B and Garnick MB: Abarelix (PPI-149), a novel and potent GnRH antagonist,
induces a rapid and profound reduction in testosterone and PSA in advanced prostate
cancer patients (PrCa). Presented at the American Urologic Association, May 1-6, 1999.
Nett TM, Allen MC, Wieczorek M, Glodé LM: A gonadotropin-releasing hormone agonist
(GnRH-A) linked to pokeweed antiviral protein (PAP) decreases the ability of the pituitary
gland to secrete LH. Society for the Study of Reproduction, August 1999 (Abstract #430).
Reznikov LL, Trollinger DB, Miller HL, Emmick JA, Johannes WU, Kim S-H, van
Bokhoven A, Tryon VV, Glodé LM, Miller GJ and Dinarello CA: Cytokine expression in
normal and malignant prostate epithelium. Focus on IL-18 system. European Cytokine
Network, volume 11, 2000 (Abstract #26027).
Duncan MW, Fung K, Zirrolli J, Basile F, Glodé LM and Miller JY: Qualitative and
quantative proteomics applied to the identification of cancer biomarkers in biological
fluids. Submitted to the IMAT PI Meeting, sponsored by the National Cancer Institute,
June 2001.
Abouelfadel Z, Miller GJ, Glodé LM, Akduman B, Hooda M, Donohue RE, Nedrow A,
Crawford ED: High Gleason Sums and Lower PSA in a Single Institution over the Past
Decade. Proceedings of American Society of Clinical Oncology 20:153b (Abstract #756),
2001.
Brian D. Kavanagh; David A. Raben; Marcus Chen; Robert Quaife; Chris Kelsey; L
Michael Glodé; Andrew Kraft; Tracey Schefter; E David Crawford. Indium-111
Capromab pendetide staging for rising PSA after prostatectomy: Implications for salvage
radiotherapy. Submitted to AUA.
Bakemeier RF, Glodé LM, Bondy J, Bair C, Montour M, Dempsey B and Winn RA:
Further evolution of the University of Colorado Cancer Center student cancer research
fellowship program, 1998-2003. Presented at the annual meeting of the American
Association of Continuing Education, October 2003.
Tyagi A, Agarwal C, Glodé LM, and Agarwal R: Silibinin efficacy in human bladder
transitional cell carcinoma: modulation of cell cycle and apoptosis cascades. AACR, 2004.
Singh R P, Sharma G, Dhanalakshmi S, Glodé LM, and Agarwal R: Silibinin inhibits
human bladder transitional-cell papilloma RT4 tumor xenograft growth in athymic nude
mice. AACR, 2004.
Agarwal R, Su L-J, Flaig T, Harrison GS, Gustafson D, and Glodé LM: A phase I clinical
study of silibinin in patients with prostate cancer. Prostate Cancer Foundation, October
2004.
19
Glodé 10/14
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
Werahera PN, Hedlund T, Glodé LM, Easterday K, Crawford ED, Lucia S, Crighton F,
Stewart JS, Robischon M, Miller GJ. Proliferative tumor doubling times of prostatic
carcinoma measured by in vivo bromodeoxyuridine (BrdU) labeling and flow cytometry
analysis. Submitted AUA, 2005.
Flaig T, Barqawi AB, Kane M, Miller G, Crawford E D , and Glodé LM: A Phase II trial
of dexamethasone, 1,25-dihydroxyvitamin D and carboplatin in patients with hormone
refractory prostate cancer. Submitted ASCO Prostate Symposium, 2005.
Flaig TW, Agarwal R, Su L, harrison GS, Gustafson D, and Glodé LM: A Phase I study of
silibinin in hormone refractory prostate cancer. Submitted ASCO, 2005.
Hussain M, Petrylak D, Dunn R, Vaishampayan U, Lara PN, Chatta G, Nanus D, Glodé
LM, Trump D, Chen H, Smith DC. Trastuzumab (T), Paclitaxel (P), Carboplatin (C) and
Gemcitabine (G) in the Treatment of Advanced HER2-positive Urothelial Cancer: Results
of a Multi-Center PhaseII NCI Trial. ASCO, 2005.
Flaig TW, Su L, Harrison G, Agarwal R, and Glodé LM: Silibinin synergizes with
mitoxantrone to decrease cell viability in prostate cancer cells. ASCO Prostate
Symposium, 2006.
Kantoff PW, Glodé LM, Tannenbaum SI, Bilhartz DL, Pittman WG, Schuetz TJ:
Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients
(pts) with hormone-refractory prostate cancer (HRPC). ASCO Prostate Symposium, 2006.
Attia, S, Eickhoff J, Wilding G, McNeel D, Blank J, Rezazadeh H, Jumonville A,
Eastmand M, Shevrin D, Glodé LM, Liu G: Randomized phase II trial of doectaxel, with or
without doxercalciferol, in androgen-independent prostate cancer. ASCO, June 2007.
Flaig, T, Glodé LM, Gustafson D, VanBokhoven A, Tao Y, Wilson S, Su L-J, Li Y,
Harrison G, Agarwal R, Crawford ED, Lucia S, Pollak M: A pilot study of oral silybinphytosome followed by prostatectomy in patients with localized prostate cancer, AACR
April 2009.
Thomas W. Flaig, L. Michael Glode, Daniel Gustafson, Adrie VanBokhoven, Yuzhen Tao,
Shandra Wilson, Lih-Jen Su, Yuan Li, Gail Harrison, Rajesh Agarwal, E. David Crawford,
Scott Lucia, Michael Pollak. University of Colorado Denver, Aurora, CO, Colorado State
University, Fort Collins, CO, McGill University, Montreal, QC, Canada: A pilot study of
oral silybin-phytosome followed by prostatectomy in patients with localized prostate
cancer. ASCO 2009.
P.W. Kantoff, T.J. Schuetz, B. Blumenstein, L.M. Glode, D.L. Billhartz, J. Gulley, J.
Schlom, R. Laus, and W. Godfrey: Overall survival (OS) analysis of a prospective
randomized Phase II controlled study of a poxviral-based PSA targeted immunotherapy, in
metastatic castration-resistant prostate cancer (mCRPC). ASCO 2009.
W.R. Godfrey, B.A. Blumenstein, T.J. Schuetz, L.M. Glode, D.L. Billhartz, J.L. Gulley, P.
Arlen, J. Schlom, R. Laus, and P.W. Kantoff.; Further analysis of a Phase II randomized
controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic
castration-resistant prostate cancer (mCRPC). ECCO 2009.
AE Frankel, A Thorburn, ML Glode: Compositions and Methods for Treating Bladder
Cancer: The present invention provides methods and compositions for treating bladder
cancer. In particular, the present invention provides a fusion protein comprising a toxin
moiety that is linked to an epithelial growth factor (EGF) moiety. ASCO 2012.
INVITED LECTURES (representative)
20
Glodé 10/14
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
“Prostate Cancer -- Screening, Surgery, Radiation or Observational Therapy: Outcomes
and Costs”. Department of Medicine Grand Rounds, University of Colorado Health
Sciences Center, October 1997, Denver CO.
“Cell Biology for Clinicians”. American Association for Cancer Research Course
Molecular Biology for Clinical Oncologists. October 22-26, 1997, Beijing, China.
“Cancer Information on the World Wide Web”. American Society of Clinical Oncology
Annual Fall Meeting. November 7-9, 1997, Orlando FL.
“Prostate Cancer Treatment After Hormone Failure”. The Institute for Research and
Education Health System Minnesota Fall Oncology Lecture. November 13, 1997,
Minneapolis MN.
“Oncology on the Internet“. Grand Rounds, McFarland Hospital, November 14, 1997,
Minneapolis MN.
“Potpourri of Tumor Cases”. Penrose Cancer Conference, Colorado Springs CO,
September 17-18, 1999.
“Internet Oncology Training” 11th Pittsburgh Cancer Conference, Pittsburgh PA, March
22, 2001.
“Prostatic Carcinoma”. Medicine Grand Rounds, University of Colorado Health Sciences
Center, April 2001, Denver CO.
“Treatment Options for Advanced Prostate Cancer”. Recent Advances in Prostate Cancer
conference, May 18, 2001, Boston MA.
“Prevention of Prostate Cancer - Current Data and Experimental Approaches”. First
International Prostate Cancer Congress, June 27-30, 2001, San Juan, Puerto Rico
“How to Get Information from the Internet”. 47th Annual Family Practice Review of the
University of Colorado School of Medicine, June 24-30, 2001, Estes Park CO.
“Gene Therapy”. University of Colorado School of Medicine course CLSC7500, July 16,
2001, Denver CO.
“Update on Bladder Cancer”. Exempla/Lutheran Bladder Cancer Support Group, July 24,
2001, Denver CO
“Prostate Cancer”. Cancer Center Summer Students, August 1, 2001, Denver CO.
Future Directions in Urology Meeting, Aug. 8-10, 2013.
International Prostate Cancer Update Meeting, Feb. 19-21, 2014.
21